NasdaqGS - Nasdaq Real Time Price USD

Amgen Inc. (AMGN)

Trade AMGN on Coinbase
337.42 +5.85 (+1.76%)
At close: May 21 at 4:00:01 PM EDT
337.86 +0.44 (+0.13%)
After hours: May 21 at 7:59:59 PM EDT
Chart Range Bar
Loading chart for AMGN
Chart does not reflect overnight price.

News headlines Amgen is navigating leadership changes while maintaining a strong revenue outlook and pipeline potential. Recent reports highlight the company's financial strategies and market challenges, particularly regarding its drug Tavneos amid safety concerns.

Amgen is navigating leadership changes while maintaining a strong revenue outlook and pipeline potential. Recent reports highlight the company's financial strategies and market challenges, particularly regarding its drug Tavneos amid safety concerns.

Updated 8m ago · Powered by Yahoo Scout
  • Previous Close 331.57
  • Open 330.00
  • Bid 322.34 x 100
  • Ask 323.98 x 100
  • Day's Range 329.09 - 337.63
  • 52 Week Range 267.83 - 391.29
  • Volume 1,860,408
  • Avg. Volume 2,669,546
  • Market Cap (intraday) 182.207B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 23.48
  • EPS (TTM) 14.37
  • Earnings Date (est.) Aug 4, 2026
  • Forward Dividend & Yield 10.08 (2.99%)
  • Ex-Dividend Date May 15, 2026
  • 1y Target Est 352.23

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

www.amgen.com

31,500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AMGN

View More

Performance Overview: AMGN

Trailing total returns as of 5/21/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMGN
4.59%
S&P 500 (^GSPC)
8.77%

1-Year Return

AMGN
28.09%
S&P 500 (^GSPC)
27.39%

3-Year Return

AMGN
65.60%
S&P 500 (^GSPC)
77.62%

5-Year Return

AMGN
57.35%
S&P 500 (^GSPC)
79.16%

Earnings Trends: AMGN

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 8.62B
Earnings 2.8B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
2B
4B
6B
8B
 

Analyst Insights: AMGN

View More

Analyst Price Targets

200.00 Low
352.23 Average
337.42 Current
427.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 5/14/2026
Analyst Piper Sandler
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 432 -> 427
 

Statistics: AMGN

View More

Valuation Measures

Annual
As of 5/20/2026
  • Market Cap

    179.05B

  • Enterprise Value

    224.33B

  • Trailing P/E

    23.07

  • Forward P/E

    14.90

  • PEG Ratio (5yr expected)

    2.19

  • Price/Sales (ttm)

    4.84

  • Price/Book (mrq)

    19.48

  • Enterprise Value/Revenue

    6.03

  • Enterprise Value/EBITDA

    13.46

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.96%

  • Return on Assets (ttm)

    8.35%

  • Return on Equity (ttm)

    101.32%

  • Revenue (ttm)

    37.22B

  • Net Income Avi to Common (ttm)

    7.8B

  • Diluted EPS (ttm)

    14.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.04B

  • Total Debt/Equity (mrq)

    623.75%

  • Levered Free Cash Flow (ttm)

    7.44B

Compare To: AMGN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: AMGN

Research Reports: AMGN

View More

People Also Watch